Categories
Credit Cards

Merrill Lynch Stick to The Buy Rating of theirs for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, which is roughly 9.11 % above the existing share price of $76.07.

Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the very first quarter of 2021.

The present opinion among eleven TipRanks analysts is actually for a moderate Buy rating of shares in CVS Health, with an average price target of $84.

The analysts priced targets range from a high of $101 to a low of $61.

In the latest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net gain of $3.25 billion. The company’s market cap is $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is presently ranked with four stars on a 0 5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It runs through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management solutions. The Long or retail Term Care segment includes offering of prescription drugs as well as assortment of general merchandise.

The Health Care Benefits segment offers traditional, consumer-directed and voluntary health insurance products and similar services, including medical, pharmacy, dental, behavioural health, medical management abilities. The Corporate segment involves in offering management and administrative services. The company was developed by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Leave a Reply

Your email address will not be published. Required fields are marked *